Skip to main content
Call 24/7: 1-800-400-1805
1-800-400-1805 Free Case Review
Sign In Join Free

choosing a clinical trial when youre stage 2 peritoneal - what actually matters

Patient · · 41 views
So I'm at the point where my oncologist is throwing a few trials at me and I'm trying to figure out which one makes sense for my situation. Stage II peritoneal, diagnosed November, and I've already done the math on HIPEC timing and recovery windows. But the trial piece is different.

I've been tracking what seems to matter and what's just noise. First thing is making sure the trial actually includes your specific type. Peritoneal versus pleural is night and day and I've seen people waste months on trials that were basically pleural-focused even though they said they took both. Check the inclusion criteria against your actual pathology report, not just what the recruiter tells you.

Second is the trial design itself. Some of these are comparing chemo regimens, some are looking at immunotherapy combinations, some are testing new drug candidates. You need to understand what the control arm actually is. If you're stage II and they're offering you standard chemo versus experimental chemo, that's different than standard chemo versus nothing. I've been reading through ClinicalTrials.gov and the protocols actually matter more than the institution name.

Third thing nobody really talks about is logistics. I'm in Cleveland and most of the serious peritoneal trials seem to be running out of a handful of places. Travel, treatment frequency, how many scans they need, whether you can do follow-up locally or if you have to go back for everything. I work through all this in my journal because it affects whether you can actually stick with it for two years.

Last piece is the data they've already published. If a trial has interim results available, read them. Not the press release version, the actual numbers. Response rates, survival curves, toxicity profiles. My doctor told me one trial sounded good until I found their six month data and the peritoneal cohort wasn't separating from historical controls yet.

I'm still deciding between two right now. One has better early data but requires monthly infusions in Boston. One is newer but closer to home. Different calculation for different people but those are the pieces I'm weighing.

12 Replies

Veteran
Man, I respect how methodical you're being about this. That's the right mindset. I'm pleural not peritoneal but the trial logic is the same and it's kept me from some dead ends.

One thing that bit me was not digging hard enough into what "comparable" actually means in trial speak. My first oncologist in San Diego said my Stage II fit three different trials. Turns out two of them were designed when pleural staging was different and their control arm data was from 2019. I wasted two months going through intake before I caught it. Your point about reading actual interim data instead of the recruiter's pitch is solid. That's the move.

The logistics piece is real too. I did my surgery at Scripps in December and my VA claim is still stuck in bureaucracy hell, so I needed treatment I could do locally. I turned down a trial at MD Anderson because even though the numbers looked better, I'd have been flying to Houston every month for follow-up imaging. At some point that wears you down and you start missing appointments or skipping scans.

One thing I'd add since you're tracking all this anyway. Ask them point blank what happens if you have to drop out. Not trying to be doom and gloom but if your trial requires you to be enrolled for 24 months and something changes at month 14, do you lose access to the drug? Can you roll over to standard treatment? I didn't ask that question early enough and it cost me options later.

Boston versus home is a tough call. I'd probably lean toward data you can actually trust over convenience but that's easy for me to say sitting here in San Diego.
Patient
Yeah that staging thing is exactly what I'm terrified of. The peritoneal staging literature shifted too and I keep wondering if some of these trials are using older criteria that don't actually match current TNM. Did you end up asking your oncologist to pull the actual protocol documents or did you have to hunt those down yourself? I'm trying to figure out if that's standard or if I need to be more aggressive about getting my hands on the unredacted versions.
Veteran
The toxicity data piece you mentioned is what clinched it for me too. My trial coordinator kept pushing response rates but I dug into their adverse event tables and the peritoneal guys had way more GI complications than the pleural cohort, which matters when you're already dealing with that anatomy. Don't let them gloss over the safety stuff.
Patient
I'm dealing with this exact same thing right now, so I'm glad you laid this out because honestly the oncology team kind of glosses over some of these details when they're pitching trials. You're right that the inclusion criteria piece is critical. I pulled my pathology report and cross-referenced it against three different trial protocols back in December and found out one of them was technically open to peritoneal but their primary endpoint was pleural response. That would've been nine months of my time for a trial not really designed around my diagnosis.

The control arm thing you mentioned really stuck with me. My oncologist kept saying "well it's either this new combination or standard carboplatin-pemetrexed" but didn't emphasize that I'd be randomized into one or the other. That's... pretty different than knowing going in what I'm getting. I found the interim data for one trial and yeah, the toxicity profiles matter more than I initially thought. One option had better response rates but the grade 3+ neuropathy was significantly higher and I'm already dealing with some baseline neuropathy issues so that changes the calculation.

The logistics piece is something I journal about constantly. I'm weighing a trial at the Cleveland Clinic that's local versus one at another major center that would mean monthly trips. Cost of travel, time off work I can't really afford to take, whether my support system can handle it. I know that sounds secondary to the science but people drop out of trials because of logistics all the time and then your data's incomplete and you've wasted months. My oncologist at Cleveland Clinic actually was honest with me about which trials she thought had the strongest peritoneal-specific data, not just which ones she could enroll me in easiest.

What two are you weighing? The Boston one sounds like it might be one I've looked at.
Medical ✓ Expert Response
This is one of the most clear-eyed breakdowns of trial selection I've seen from a patient perspective. You've basically landed on the same framework we walk through in tumor board when we're advising on enrollment.

The control arm point is the one most people miss. I had a patient last spring who almost enrolled in a trial where the control arm was actually below the current standard of care for peritoneal disease. Not unethical, they were transparent about it, but it wasn't obvious from the summary language. The PRODIGE 7 trial results from 2018 are still shaking up how we think about HIPEC combinations and what "standard" even means for peritoneal, so that baseline matters enormously when you're evaluating what you're actually being randomized against.

The Boston versus local question is genuinely hard and there's no universal answer. What I'd add is that the frequency question changes over time for many trials. Months one through three tend to be intensive regardless, and then protocols often allow some flexibility for follow-up imaging to be done closer to home. Worth asking the trial coordinator specifically about that, not just the recruiting oncologist.

One thing you didn't mention is the amendment history on the protocol. If a trial has had two or three amendments in the first year, that sometimes signals they've been adjusting eligibility or dosing based on early safety signals. Not disqualifying, but worth knowing.

Your instinct to read the actual data rather than the press release is exactly right. And please do loop your oncologist in on whichever direction you're leaning before you finalize anything. They know your pathology in ways no trial summary can account for.
3 found this helpful
Patient
I'm basically doing exactly this right now so I feel like I'm looking in a mirror. I've narrowed it down to two as well and the Boston versus local thing is real. My oncologist at Cleveland Clinic initially pushed me toward the trial with the stronger interim data, which is running out of Brigham and Women's, but then we actually sat down and mapped out what monthly infusions for 24 months looks like when you're trying to maintain any quality of life between treatments.

The thing that changed my thinking was pulling the actual protocol documents from ClinicalTrials.gov instead of just reading the summaries. One trial I was considering said it included peritoneal cases but when I got into the nitty gritty, the peritoneal cohort was only 12 patients total and they were mixed with stage I and III. Not exactly robust data for someone at stage II specifically. I actually called the research coordinator and asked point blank what their peritoneal response rate was at six months versus the pleural patients. She was honest that the numbers weren't separating yet.

I've been keeping a detailed symptom and treatment response journal since my diagnosis in November, so I'm also factoring in how the trial protocols might affect my ability to track what's actually happening with my own body. Some trials want so many scans and labs that you're essentially in the system constantly versus others that are more spaced out.

The closer trial to me has less published data which is uncomfortable, but their phase one results looked solid enough and the logistics piece is genuinely not nothing when you're managing a stage II diagnosis. I'm planning to ask about their plans for publishing interim results and what the timeline looks like. That might be the deciding factor for me.

Have you been able to get your hands on the actual protocol documents or are you still working with the recruiter summaries?
Medical ✓ Expert Response
What you've laid out here is honestly one of the most thoughtful breakdowns I've seen from someone in the thick of it. The point about checking inclusion criteria against your actual pathology report, not just trusting recruiter language, that's something I've watched people miss so many times over 12 years of this work.

The control arm piece is so real. I sat with a family last spring going through an informed consent document line by line and they had no idea the "standard care" arm was a regimen the treating oncologist wouldn't have chosen outside of the trial context. That conversation shifted everything for them.

On the Boston versus closer to home question, I don't think there's a clean answer but I will say that I've seen people underestimate the cumulative toll of distance. Monthly travel for two years isn't just logistics, it's energy, it's relationships, it's whether you can sustain it when you're having a hard month. Research out of the Journal of Clinical Oncology has looked at treatment adherence and distance is a real factor in outcomes, not just comfort.

Journaling through this is genuinely useful, not just emotionally but because you're building a record of your own reasoning that you can come back to when things shift.

And if the weight of this decision starts to feel like too much to carry in your head alone, talking with an oncology social worker or counselor who specializes in this can help you sort what's fear versus what's actual data. Sometimes those get tangled.
3 found this helpful
Patient
That's exactly why I'm keeping the actual protocols saved, not just the summaries. The informed consent documents are where the real picture lives and I've caught things in there that directly contradict what gets said in the initial consultation calls. One trial made it sound like the experimental arm was this breakthrough option but buried in section 4.2 was that the control group was getting a more aggressive chemo schedule anyway, so the actual comparison wasn't as clean as advertised. It's frustrating because you want to trust these programs but the devil really is in those details, especially when you're trying to make a decision that affects the next couple years of your life.
Medical ✓ Expert Response
Building on what Patricia raised about staging criteria, this is actually a real problem in peritoneal trials right now. The Peritoneal Surface Oncology Group International updated their staging consensus in 2016 and some trials still use the older Sugarbaker PCI (peritoneal cancer index) cutoffs as eligibility criteria. So a patient who's stage II by current standards might have been staged differently under the criteria a trial was designed around, and that mismatch can affect whether the published cohort data even applies to you.

The thing I'd add to your framework is asking specifically which PCI threshold the trial uses for enrollment, because that number tells you a lot about who's actually in their data. If their peritoneal cohort was enrolled at PCI under 20 and yours is closer to that ceiling, your outcomes may look more like their higher-burden subgroup than their overall response numbers suggest.

Your instinct to read the actual interim data is exactly right. Talk to your own oncologist about how your specific PCI and pathology map onto the trial's enrolled population before weighting the published numbers too heavily.
3 found this helpful
Family
This is exactly the kind of breakdown I wish I'd had when my dad was considering trials last year. The logistics piece especially - everyone focuses on efficacy and nobody mentions you can't actually do a trial if you're exhausted from traveling every month.
Medical ✓ Expert Response
What you've laid out here is genuinely one of the more rigorous frameworks I've seen a patient put together on their own, and I mean that. The inclusion criteria point especially. The CARTO peritoneal registry data from 2021 showed that peritoneal mesothelioma patients were enrolled in pleural-dominant trials at a rate that probably surprised a lot of people involved in those trials. So yes, pathology report in hand, not the recruiter's summary.

The control arm question is where I'd push you a little further. For stage II peritoneal, the "standard of care" designation is genuinely contested in the literature right now. The DREAM trial results complicated how we think about pemetrexed combinations, and if a control arm is built around assumptions from pleural data applied to peritoneal patients, that's worth a direct conversation with the principal investigator, not just the coordinator.

On the Boston vs. closer question, I'd look hard at what months 4 through 14 look like logistically, not month one when motivation is high. I had a patient in 2022 who chose a trial at a site three hours from home partly because they offered lodging assistance through their research budget, which covered about $1,800 of travel costs over the first six months. Those details sometimes exist and just don't get mentioned upfront.

The interim data instinct is right. Ask specifically whether the peritoneal subgroup has been analyzed separately, because pooled response rates with pleural patients can obscure a lot.

Talk to your oncologist about all of this, and honestly, if you haven't already connected with a PI directly, that conversation is worth requesting.
2 found this helpful
Family
Your breakdown is solid and honestly way more thorough than most people do with this. The peritoneal versus pleural thing is huge and I see it constantly in clinical settings. People assume a trial is a trial but the biology is completely different, treatment protocols are different, and yeah the data might not even apply to their specific type.

My dad has pleural mesothelioma stage IV so different beast entirely, but I've watched him go through palliative care now since October and I've learned the hard way that the logistics piece you mentioned is absolutely critical. We looked at a couple of trials earlier in his diagnosis and one required weekly visits to Ann Arbor. Sounds manageable until you're actually dealing with someone who's fatiguing, dealing with side effects, and you're coordinating around his symptoms. We ended up staying local with his oncologist at Northwestern and honestly that decision probably extended his quality time with us because he wasn't spending energy on travel.

The interim data thing cannot be overstated. I pulled protocols for my dad and cross-referenced them with PubMed and it's wild what you find when you actually read the numbers versus the trial summary. One showed impressive response rates but when you looked at the median overall survival it wasn't budging compared to standard treatment. That matters.

One thing I'd add since you're still deciding: talk to the actual trial coordinators not just the doctors. Ask them specifically about your peritoneal diagnosis. Ask what percentage of their enrolled patients have your stage and histology. Ask about dropout rates. They'll tell you things the oncologist doesn't always think to mention.

The Boston versus closer to home calculation is real. That's not a small thing when you're looking at months or years of treatment.

Share Your Experience

Sign in or create a free account to share your experience.

Sign In Create Account

Discussions in this community are for informational and emotional support purposes only. They do not constitute legal advice, medical advice, or an attorney-client relationship. Always consult a qualified professional for advice specific to your situation. Community Guidelines

Call Now: (800) 400-1805 Free Case Review • Available 24/7